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Abstract
Background: Since diabetes mellitus (DM) is the leading cause of end stage renal disease (ESRD), this study aimed
to develop a 5-year ESRD risk prediction model among Chinese patients with Type 2 DM (T2DM) in primary care.
Methods: A retrospective cohort study was conducted on 149,333 Chinese adult T2DM primary care patients without
ESRD in 2010. Using the derivation cohort over a median of 5 years follow-up, the gender-specific models including
the interaction effect between predictors and age were derived using Cox regression with a forward stepwise
approach. Harrell’s C-statistic and calibration plot were applied to the validation cohort to assess discrimination and
calibration of the models.
Results: Prediction models showed better discrimination with Harrell’s C-statistics of 0.866 (males) and 0.862 (females)
and calibration power from the plots than other established models. The predictors included age, usages of anti-
hypertensive drugs, anti-glucose drugs, and Hemogloblin A1c, blood pressure, urine albumin/creatinine
ratio (ACR) and estimated glomerular filtration rate (eGFR). Specific predictors for male were smoking and
presence of sight threatening diabetic retinopathy while additional predictors for female included longer
duration of diabetes and quadratic effect of body mass index. Interaction factors with age showed a greater
weighting of insulin and urine ACR in younger males, and eGFR in younger females.
Conclusions: Our newly developed gender-specific models provide a more accurate 5-year ESRD risk predictions
for Chinese diabetic primary care patients than other existing models. The models included several modifiable
risk factors that clinicians can use to counsel patients, and to target at in the delivery of care to patients.
Keywords: Type 2 diabetes mellitus, Prediction, Risk, End stage renal disease, Primary care
Background
Current prevalence of diabetes mellitus is one in 11
adults, affecting 415 million people, and it is estimated
to increase to 642 million all over the world [1]. Diabetes
is the leading cause of end-stage renal disease (ESRD),
which is an irreversible loss of renal function and is fatal
without receiving renal replacement therapy [2, 3]. The
coexistence of diabetes and ESRD elevate the risk of
mortality significantly [4–6]. Although the number of
patients with ESRD account for only 0.1%–0.2% of the
total population in developed countries, health spending
on renal failure was 2–3% of the total healthcare ex-
penditure [7]. Given available effective treatments in re-
duction of development and progression of diabetic
kidney disease [8], identification of diabetic patients who
are at high risk of ESRD is needed to allow target deliv-
ery of proper healthcare and facilitate service policy
planning.
Several national guidelines including the National In-
stitute for Health and Care Excellence from UK and the
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American Diabetes Association recommend the regular
screening for diabetic kidney disease in diabetic patients
[8, 9]. On one hand, some prediction models established
from general population like QKidney model [10–12] in-
cluded diabetes as one of the predictors only, without
examining other clinical indicators such as haemoglobin
A1c (HbA1c), estimated glomerular filtration rate
(eGFR) and urine albumin to creatinine ratio (ACR),
which are associated with the risk of developing ESRD
[11, 13, 14]. Given the 3 to 5 folds higher risk of ESRD
incidence in diabetic patients compared to non-diabetic
patients [10], the type and magnitude of the association
of the predictors for ESRD for diabetic population may
differ from those for non-diabetic population. Only a
few studies have established risk prediction models in
ESRD such as the New Zealand Diabetes Cohort Study
and the Action in Diabetes and Vascular Disease: Pre-
terax and Diamicron-MR Controlled Evaluation (AD-
VANCE). These studies were done predominantly in a
non-Chinese diabetic population [4, 15]. Studies have
shown different ESRD incidence rates in different racial
groups including Chinese populations [16–18]. Hence,
these models may not be applied to a Chinese diabetic
population. While a ESRD risk prediction model was de-
rived from Chinese diabetic patients managed in second-
ary care, one of the predictors in this model, haematocrit,
is not routinely available in primary care and thus this
model may be more suitable to be applied in secondary
care than in primary care [19]. In addition, a previous
study reported that there was a potential difference in pre-
dictors of ESRD incidence between male and female [10],
but most of established models without stratifying gender
may not obtain accurate predicted ESRD risk. Therefore,
there is a need to develop a more accurate prediction
model by stratifying gender for ESRD risk based on Chin-
ese primary care patient with diabetes.
Since there were no population-based studies on ESRD
risk prediction models specific to Chinese primary care
diabetic population, the aim of this study was to develop
a 5-year ESRD risk prediction model among Chinese pa-
tients with Type 2 DM (T2DM) in primary care.
Methods
Study design
This is a population-based retrospective cohort study.
Subject inclusion criteria included (1) Chinese, (2) age
between 18 and 79 years old, (3) clinically diagnosed
with T2DM, and (4) no previous record of CVD and
ESRD. All subjects received primary care services from
one of the 74 general outpatient clinics of the Hong
Kong Hospital Authority (HA) between 1 January 2010
and 31 December 2010 and their clinical data were re-
trieved from the administrative database of the HA. The
HA is the largest governmental organisation managing
at least half of DM patients under primary care in Hong
Kong. Data were available from a territory-wide study
for the evaluation of local diabetic programmes [20].
Diagnosis of T2DM was clinically identified by the Inter-
national Classification of Primary Care-2 (ICPC-2) code
of ‘T90’. ESRD was identified by the International Clas-
sification of Diseases, Ninth Edition, Clinical Modifica-
tion (ICD-9-CM) of 250.3x, 585.x and 586.x, or eGFR
<15 ml/min/1.73m2. Baseline was defined as the patient’s
first attendance date of general outpatient clinics during
January 2010 and 31 December 2010. Each patient was
follow-up until the date of diagnosis of ESRD event,
death or last follow-up as censoring in 30 November
2015, whichever occurred first.
Potential predictors
The potential predictors included socio-demographics,
disease characteristics, treatment modalities and clinical
parameters. Socio-demographics included gender, age
and smoking status. Disease characteristics consisted of
self-reported duration of DM, diagnosed hypertension
and presence of sight threatening diabetic retinopathy
(STDR). Diagnosis of hypertension was identified by the
ICPC-2 of K86 to K87. STDR included pre-proliferative,
proliferative diabetic retinopathy or maculopathy. Treat-
ment modalities consisted of the usages of anti-
hypertensive drugs, anti-glucose oral drugs, insulin and
lipid-lowering agents. Clinical parameters were body
mass index (BMI), waist circumference, HbA1c, systolic
blood pressure (SBP), diastolic blood pressure (DBP),
lipid profile (low-density lipoprotein-cholesterol (LDL-
C) and total cholesterol to high-density lipoprotein-
cholesterol ratio (TC/ HDL-C ratio)), triglyceride, urine
ACR and eGFR. All laboratory assays were performed in
accredited laboratories by the College of American Pa-
thologists, the Hong Kong Accreditation Service or the
National Association of Testing Authorities, Australia.
Data analysis
Missing data were handled by multiple imputation [21].
Specifically, each missing value was imputed five times
using chained equation method. The same analysis was
performed for each imputed dataset and the resulting five
sets of results were aggregated by the Rubin’s rule [22].
The risk prediction models were developed separately
for each gender since several studies discovered that
there was a potential difference in predictors of ESRD
incidence between male and female [23–28]. For each
gender, all subjects were randomly divided on a 2:1
basis, with two-third subjects being the derivation co-
hort to develop the risk prediction models, and the
remaining one-third being the validation cohort to valid-
ate the derived prediction models. Independent t-tests or
chi-square tests were used to evaluate if there was any
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significant difference in potential predictors between the
two cohorts.
Cox proportional hazards regression with forward
stepwise method was performed to obtain a risk predic-
tion model using the derivation cohort. The cutoff p-
values for variable entering and leaving the model for
each step were 0.05 and 0.1, respectively. Since previous
literature showed that some predictors such as blood
pressure had curvilinear relationship with adverse event
[29, 30], the quadratic terms of these predictors were
also considered in our model. Furthermore, another
study revealed that the effects of some factors, such as
blood pressure, may vary across age [29]. Thus, the
interaction effects between age and the predictors were
also assessed. The proportional hazards assumption was
checked by examining plots of the scaled Schoenfeld re-
siduals against time for the predictors. Any non-random
pattern implies a violation of the proportional hazards
assumptions and thereafter transformation of covariates
would be attempted. All models in our study fulfilled
proportional hazards assumption.
The performance of our model, ADVANCE and New
Zealand ESRD risk scores for T2DM was compared
using the validation cohorts [4, 15]. The New Zealand
model were developed based on European, Maori, Pa-
cific, East Asian, Indo-Asian from New Zealand and in-
cluded 10 predictors which were age, gender, duration
of DM, smoking status, HbA1c, SBP, urine ACR, eGFR,
history of CVD and ethnicity. Meanwhile, the AD-
VANCE model were established across 20 countries
and included 7 predictors which were gender, HbA1c,
SBP, urine ACR, eGFR, retinopathy and education level.
Since we did not have educational data, we assumed no
attendance at education until at least 16 years of age in
the ADVANCE risk model. For each model, the Har-
rell’s C statistic, D statistic and R2 statistic were com-
puted to assess the predictive power. A Harrell’s C
statistics of less than 0.7 indicates limited discriminat-
ing power, 0.7 to 0.9 is acceptable, and higher than 0.9
suggests strong discrimination of the predictive models
[31]. The D statistic is a measure of discrimination with
higher value implies better discrimination. The R2 stat-
istic measures the explained variation in the model with
higher value indicating better performance. After boot-
strapping of size 500, the corresponding 95% confi-
dence intervals (CIs) were obtained. The calibration
plots were also displayed to compare the mean of pre-
dicted risk at 5 years with the observed ESRD risk,
which was obtained by 5-year Kaplan-Meier estimate,
by deciles of predicted risk.
All significance tests were two-tailed and those with p-
values less than 0.05 were considered statistically signifi-
cant. The statistical analysis was performed in STATA
Version 13.0.
Results
There were a total of 149,333 Chinese T2DM patients
aged between 18 and 79 years receiving care in primary
care clinics of HA between 1 January 2010 and 31 De-
cember 2010. After excluding 10,789 patients had CVD
at baseline, 21,426 patients had ESRD at baseline and
609 patients had no follow-up record, the remaining
116,509 diabetic patients, including 54,472 males and
62,037 females were included in the main analysis. The
three lowest data completion rates for STDR, urine ACR
and waist circumference were 70%, 72% and 83%, re-
spectively, while other potential predictors were higher
than 90%. During a median follow-up period of 5 years
(range: 0.04 to 6.04 years), the incidence rate of ESRD
per 1000 person-years was 0.41 (95% CI: 0.40–0.43),
while that in male and female groups were 0.50 (95% CI:
0.47–0.52) and 0.34 (95% CI: 0.32–0.36), respectively.
For each gender, Table 1 compares the baseline charac-
teristics between derivation and validation cohorts after
multiple imputation. For the derivation cohorts, the
mean ages for male and female were 61.4 and 62.7 years,
respectively. The two cohorts did not show any signifi-
cant differences in all potential predictors for each
gender.
After selecting the predictors by forward stepwise
method (shown in Additional file 1: Table S1a and 1b),
Table 2 and Additional file 2: Table S2 show the esti-
mated risk prediction models for each gender by Cox
proportional hazards regression. Common predictors to
both male and female included older age, usages of anti-
hypertensive drugs, anti-glucose oral drugs and insulin,
and increased SBP, urine ACR and eGFR. Moreover,
quadratic effects of HbA1c and DBP were significantly
associated with increased risk of ESRD. For male T2DM
subjects, additional predictors of ESRD risk were smok-
ing and presence of STDR. The magnitudes of the asso-
ciation for insulin and urine ACR also decreased across
age. For female T2DM subjects, additional predictors in-
cluded longer duration of T2DM and the quadratic ef-
fect of BMI. Similarly, the magnitude of the association
for eGFR also decreased across age. To summarise, the
developed risk prediction model for male included 11
predictors: age, smoking status, presence of STDR, us-
ages of anti-hypertensive drugs, anti-glucose oral drugs
and insulin, HbA1c, SBP, DBP, urine ACR and eGFR,
whereas the one for female included 12 predictors: age,
duration of T2DM, usages of anti-hypertensive drugs,
anti-glucose oral drugs and insulin, BMI, HbA1c, SBP,
DBP, urine ACR and eGFR. The formulae for the deriv-
ation of the predicted ESRD risk were shown in Add-
itional file 3: Table S3.
Table 3 compares the performance of the newly devel-
oped prediction models with ADVANCE and New Zea-
land ESRD risk scores using validation cohort. In terms
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of prediction power, both the new and the New Zealand
models performed better than the ADVANCE model for
female while there was no significant difference among
the three models for male. Figure 1 displays the calibra-
tion plot on the predicted risk and the observed ESRD
risk at 5 years in each gender. The new model demon-
strated better calibration than the other models.
Discussion
This is the first study to develop the prediction model
for ESRD risk among Chinese population-based primary
care patient with diabetes. Our findings showed that
current ESRD risk prediction models such as ADVANCE
and New Zealand had poor calibration power, which
substantially underestimated the actual risk of ESRD in
Chinese diabetic population. Our results showed that
the prediction model for ESRD should be ethnic-specific
and gender-specific. Moreover, we confirmed the im-
portance of eGFR and urine ACR in predicting ESRD
and found that the renal impairments interacted with
age on the risk of ESRD for Chinese diabetic patients.
Our model could identify diabetic patients who are at
high risk of ESRD in order to counsel patients, allow tar-
get delivery of proper healthcare and facilitate service
policy planning.
In comparison to our model, the ADVANCE and New
Zealand models had comparable discriminatory power but
lack of calibration power, indicating the apparent discrep-
ancy between observed and predicted risks. As a conse-
quence, the ultimate goal of the earlier identification for
Table 1 Baseline characteristics of derivation and validation cohorts in male and female groups
Characteristics Male Female
Derivation cohort
(n = 36,289)
Validation cohort
(n = 18,145)
Derivation cohort
(n = 41,347)
Validation cohort
(n = 20,674)
Socio-demographics
Age,years 61.4 ± 10.0 61.4 ± 10.0 62.7 ± 9.9 62.8 ± 9.8
Smoker 7627 (21.0%) 3843 (21.2%) 923 (2.2%) 411 (2.0%)
Disease characteristics
Duration of T2DM, years 6.8 ± 6.1 6.9 ± 6.4 7.4 ± 6.7 7.4 ± 6.6
Diagnosed Hypertension 24,862 (68.5%) 12,488 (68.8%) 30,857 (74.6%) 15,436 (74.7%)
STDR 2111 (5.8%) 1057 (5.8%) 1961 (4.7%) 934 (4.5%)
Treatment modalities
Anti-hypertensive drugs used 27,294 (75.2%) 13,573 (74.8%) 31,845 (77.0%) 15,980 (77.3%)
Anti-glucose oral drugs used 32,296 (89.0%) 16,102 (88.7%) 35,875 (86.8%) 17,977 (87.0%)
Insulin used 929 (2.6%) 475 (2.6%) 983 (2.4%) 509 (2.5%)
Lipid-lowering agents used 9016 (24.8%) 4639 (25.6%) 12,480 (30.2%) 6245 (30.2%)
Clinical parameters
BMI, kg/m2 25.4 ± 3.8 25.5 ± 3.8 25.6 ± 4.2 25.5 ± 4.3
Waist circumference, cm 90.7 ± 19.8 90.8 ± 17.8 87.5 ± 20.8 87.6 ± 24.5
HbA1c, % 7.2 ± 1.3 7.2 ± 1.3 7.2 ± 1.2 7.2 ± 1.2
HbA1c, mmol/mol 55 ± 14.2 55 ± 14.2 55 ± 13.1 55 ± 13.1
SBP, mmHg 134.0 ± 15.9 134.2 ± 16.1 134.6 ± 16.5 134.7 ± 16.4
DBP, mmHg 77.0 ± 9.8 77.1 ± 9.7 73.7 ± 9.7 73.7 ± 9.6
LDL-C, mmol/L 2.9 ± 0.8 2.9 ± 0.8 3.0 ± 0.8 3.0 ± 0.8
TC/HDL-C ratio 4.3 ± 1.2 4.3 ± 1.2 4.0 ± 1.1 4.0 ± 1.1
Triglyceride, mmol/L 1.6 ± 0.9 1.6 ± 0.9 1.6 ± 0.9 1.6 ± 0.9
Urine ACR, mg/mmol 6.8 ± 40.6 7.0 ± 41.7 6.8 ± 37.9 7.2 ± 52.0
eGFR, ml/min/1.73m2
≥ 90 26,683 (73.5%) 13,277 (73.2%) 29,839 (72.2%) 14,857 (71.9%)
60–89 8694 (24.0%) 4381 (24.1%) 9906 (24.0%) 5041 (24.4%)
< 60 912 (2.5%) 487 (2.7%) 1601 (3.9%) 776 (3.8%)
T2DM Type 2 Diabetes Mellitus, STDR Sight Threatening Diabetic Retinopathy, BMI Body Mass Index, HbA1c Haemogloblin A1c, SBP Systolic Blood Pressure, DBP
Diastolic Blood Pressure, LDL-C Low Density Lipoprotein-Cholesterol, TC Total Cholesterol, HDL-C High-density Lipoprotein-Cholesterol, ACR Albumin/Creatinine
Ratio, eGFR estimated Glomerular Filtration Rate
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patients at high risk of ESRD may be defeated by the in-
accurate predicted risk. Current results demonstrated that
the ADVANCE and New Zealand models underestimated
risk among Chinese diabetic population. Ethnic disparities
in the risk of ESRD may be a potential explanation for this
discrepancy. Although the ADVANCE model showed no
difference in the risk of ESRD between Asian and non-
Asian, numerous multi-ethnic studies showed that Asian
diabetic patients had doubled the risk of albuminuria
compared to Caucasian diabetic patients [18, 32, 33].
Meanwhile, the New Zealand model included ethnicity as
a predictor to allow the modification for the various risks
of ESRD in different ethnic groups. Nevertheless, only a
small proportion of East Asian subjects (717 out of
25,736) was included in their sample and it may not be
fully representative of a Chinese diabetic population.
Moreover, a multinational study conducted by the World
Health Organisation found that Chinese patients had a
higher prevalence of proteinuria compared to other popu-
lations [34, 35]. A recent epidemiological study also illus-
trated that the risk of ESRD in Asian diabetic population
varied widely between Chinese, Malay and Asian Indian
[36]. The ethnic differences in disease profile may be at-
tributable to genetic variants and the environmental fac-
tors such as health care policy and cultural behaviours
between diabetic populations [34–37], and thus the
Table 2 Cox regression models for predictors of developing end stage renal disease in derivation cohort
Predictors Male Female
HRa 95%CI P-value HRa 95%CI P-value
Socio-demographics
Age, years 1.06 (1.05,1.08) <0.001* 1.03 (1.02,1.05) <0.001*
Smoker (Non-smoker) 1.29 (1.11,1.50) 0.001*
Disease characteristics
Duration of T2DM, years 1.01 (1.00,1.02) 0.046*
STDR (No) 1.47 (1.18,1.84) 0.001*
Treatment modalities
Anti-hypertensive drugs used (No) 1.54 (1.21,1.97) 0.001* 1.66 (1.21,2.26) 0.002*
Oral drug (No) 1.37 (1.07,1.75) 0.011* 1.98 (1.43,2.75) <0.001*
Insulin drug (No) 9.79 (1.66,57.62) 0.012* 1.73 (1.30,2.29) <0.001*
Clinical parameters
BMI, kg/m2 0.85 (0.77,0.95) 0.002*
BMI2, kg/m2 1.003 (1.001,1.005) 0.001*
HbA1c, % 0.79 (0.64,0.98) 0.036* 0.70 (0.49,0.99) 0.046*
HbA1c2, % 1.02 (1.01,1.03) 0.002* 1.03 (1.01,1.05) 0.013*
SBP, mmHg 1.01 (1.01,1.02) <0.001* 1.01 (1.00,1.01) 0.025*
DBP, mmHg 0.93 (0.88,0.98) 0.009* 0.92 (0.86,0.98) 0.007*
DBP2, mmHg 1.0004 (1.0000,1.0008) 0.039* 1.001 (1.000,1.001) 0.017*
ln(Urine ACR + 1), mg/mmol 3.15 (2.11,4.69) <0.001* 1.45 (1.37,1.53) <0.001*
eGFR (>90 ml/min/1.73m2)
60-89 ml/min/1.73m2 2.45 (2.08,2.88) <0.001* 2.00 (0.38,10.51) 0.412
< 60 ml/min/1.73m2 8.76 (7.08,10.84) <0.001* 112.06 (23.97,523.76) <0.001*
Age interaction term
Age*eGFR(>90 ml/min/1.73m2)
60-89 ml/min/1.73m2 1.003 (0.979,1.028) 0.816
< 60 ml/min/1.73m2 0.97 (0.95,0.99) 0.006*
Age*insulin 0.97 (0.95,1.00) 0.028*
Age* ln(Urine ACR + 1) 0.99 (0.98,0.99) <0.001*
T2DM Type 2 Diabetes Mellitus, STDR Sight Threatening Diabetic Retinopathy, BMI Body Mass Index, HbA1c Hemogloblin A1c, SBP Systolic Blood Pressure, DBP
Diastolic Blood Pressure, TC Total Cholesterol, HDL-C High-density Lipoprotein-Cholesterol, ACR Albumin/Creatinine Ratio, eGFR estimated Glomerular Filtration
Rate, T2DM Type 2 Diabetes Mellitus, HR Hazard Ratio
* Significant difference (P < 0.05)
a HR > 1 indicates greater risk of event occurrence
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Table 3 Performance of new and existing end stage renal disease risk models in validation cohort for predicting 5-year risk of end
stage renal disease
Validation statistics New model ADVANCE model New Zealand model
Male
Harrell’s C statistic 0.866 (0.849,0.882) 0.858 (0.840,0.876) 0.863 (0.846,0.880)
Difference in Harrell’s C statistic in comparison with new model - 0.008 0.002
D statistic 2.458 (2.298,2.595) 2.429 (2.270,2.577) 2.482 (2.337,2.615)
R2 59.1 (55.9,61.7) 58.5 (55.1,61.6) 59.5 (56.6,62.2)
Female
Harrell’s C statistic 0.862 (0.845,0.880) 0.844 (0.822,0.865) 0.861 (0.842,0.880)
Difference in Harrell’s C statistic in comparison with new model - 0.019* 0.001
D statistic 2.410 (2.228,2.563) 2.366 (2.201,2.531) 2.493 (2.317,2.655)
R2 58.1 (54.4,61.2) 57.2 (53.1,61.2) 59.7 (56.1,63.1)
The brackets represented 95% confidence interval of corresponding validation statistic
* Significant difference in Harrell’s C statistic (P-value <0.05)
New model
Male
ADVANCE risk score
Female
Deciles of estimated risk
5-
D
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E
fo
ksir
raey
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D
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E
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ksir
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D
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E
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raey
Deciles of estimated risk
New Zealand risk score
Fig. 1 Calibration plots for observed and predicted 5-year risks of end stage renal disease (ESRD)
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prediction model for ESRD should be ethnic-specific. The
external validation should be conducted in the future
study in order to validate our model in other Chinese
populations.
The key novelty of our study was to extend on the pre-
vious models for the risk of ESRD by stratifying gender
and including age effect on the renal impairment mea-
sured by urine ACR and eGFR. This study supports
prior observations that higher risk of renal impairment
in male compared to female [23–28] and the current re-
sults prolonged this manifestation that the predictors for
the risk of ESRD between genders were different. The
reasons may be related to the genetic diversity between
genders in kidney structure and function, receptor medi-
ated influence of sex steroids on glomerular structure, as
well as response on the synthesis and discharge of cyto-
kines and growth factors [26, 27, 38]. The different
modifiable risk factors for male and female may also
suggest different approaches and therapies for the pre-
vention of ESRD. Meanwhile, a meta-analysis involving
more than 1.5 million patients in different countries
from 45 cohorts conducted by the Kidney Disease, Im-
proving Global Outcomes (KDIGO) showed that urine
ACR and eGFR were independent risk factors for both
progression of chronic kidney disease and ESRD [39].
Through the stringent evaluation with an almost inex-
haustible list of clinical variables, our finding confirmed
that the effects of urine ACR and eGFR were not dimin-
ished by other variables. In addition, the results of the
present study illustrated the interaction effect between
age and renal impairment on the incidence of ESRD,
which indicated that the impacts of urinary albumin and
kidney function were diluted by older age. This
phenomenon may be understandable because the sever-
ity of renal impairment in elderly may be certainly high,
and thus there is a relatively small room to decline as a
result of lower changes in urine ACR and eGFR among
elder patients compared to younger patients. An afore-
mentioned observational study conducted in the United
States also displayed that there is a continuous trend
with a slow progressive eGFR decline observed among
the general population after age of 40 [40]. Other predic-
tors in our model were well discussed in the literatures
[26, 27, 41]. A further study should be warranted to con-
firm the interaction effect on the incidence of ESRD be-
tween age and renal impairments, and the curvilinear
relationship between risk of ESRD and the predictors in-
cluding HbA1c and BP.
Strengths and limitations of this study
There were several strengths in the current study.
Firstly, using a large primary care Chinese T2DM popu-
lation in current study is highly representative of the
Hong Kong Chinese diabetic population managed in
primary care setting. Secondly, the clinical and labora-
tory data were systemically extracted from the HA’s
computerised administrative database, which were more
reliable and accurate. Finally, multiple imputations were
conducted to substitute the missing data so as to capture
less biased results.
On the other hand, this study has several limitations.
Firstly, retrospective rather than prospective was con-
ducted in our study design, which may cause some bias
to the results. Secondly, the risk of ESRD may be differ-
ent between non-smokers and past smokers, but our
non-smokers including past smokers was potentially bias
to the results. Thirdly, only 5-year ESRD predicted risk
was available in our model. A future study with longer
follow-up periods of 10-year is necessary to develop the
model that can forecast longer-term ESRD risks for dia-
betic populations. Fourthly, the developed models con-
sisted of 11–12 predictors, which may be difficult to be
applied in clinical practices. Lastly, only internal valid-
ation but not external validation was available in the
current study. An external validation should be war-
ranted to validate our model by using Chinese popula-
tion in other regions.
Conclusions
Our newly developed gender-specific models provide a
more accurate and valid 5-year ESRD risk predictions
for Chinese diabetic primary care patients than other
currently existing models. We confirmed the importance
of eGFR and urine ACR in predicting ESRD and found
the renal impairments interacted with age on the risk of
ESRD for Chinese diabetic patients. Our model could
identify diabetic patients who are at high risk of ESRD
and included several modifiable risk factors such as
smoking and blood pressure in order to counsel patients,
allow target delivery of proper healthcare and facilitate
service policy planning.
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